Share on StockTwits
 

Shares of Veracyte (NASDAQ:VCYT) hit a new 52-week high during trading on Friday, StockRatingsNetwork reports. The stock traded as high as $16.36 and last traded at $14.60, with a volume of 129,743 shares trading hands. The stock had previously closed at $14.67.

VCYT has been the subject of a number of recent research reports. Analysts at Cowen and Company initiated coverage on shares of Veracyte in a research note to investors on Tuesday, November 26th. They set an “outperform” rating and a $16.00 price target on the stock. Separately, analysts at Leerink Swann initiated coverage on shares of Veracyte in a research note to investors on Tuesday, November 26th. They set an “outperform” rating and a $17.00 price target on the stock. Finally, analysts at Morgan Stanley initiated coverage on shares of Veracyte in a research note to investors on Tuesday, November 26th. They set an “overweight” rating and a $16.00 price target on the stock.

Veracyte has a 52 week low of $10.88 and a 52 week high of $14.80. The stock’s 50-day moving average is $13.34 and its 200-day moving average is $13.05. The company’s market cap is $322.0 million.

Veracyte (NASDAQ:VCYT) last issued its quarterly earnings data on Monday, November 25th. The company reported ($6.59) earnings per share for the quarter. The company had revenue of $5.60 million for the quarter, compared to the consensus estimate of $3.20 million.

Veracyte, Inc is a diagnostics company focused on molecular cytology. The Company focuses on diseases that often require invasive procedures for an accurate diagnosis.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.